NAUT
Nautilus Biotechnology, Inc. [NAUT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NAUT Stock Summary
Top 10 Correlated ETFs
NAUT
Top 10 Correlated Stocks
NAUT
In the News
NAUT Financial details
Company Rating
-
Market Cap
308.99M
Income
-60.58M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
167
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-6.6
Forward P/E
-
PEG
22.9
P/S
-
P/B
1.42
P/C
-
P/FCF
-10.43
Quick Ratio
20.61
Current Ratio
21
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.5
EPS next Y
-
EPS next Q
-
EPS this Y
-0%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
7.69%
-
-
-
-
SMA20
-
SMA50
-
SMA100
100%
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-20%
ROC
-0.22%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.16-4.65
52W High
-51.38%
52W Low
-2.75%
RSI
49
Rel Volume
1.54
Avg Volume
78.9K
Volume
121.22K
Perf Week
-10.78%
Perf Month
7.46%
Perf Quarter
166.07%
Perf Half Y
148.59%
-
-
-
-
Beta
1.003
-
-
Volatility
0.11%, 0.11%
Prev Close
-5.58%
Price
1.945
Change
-13.56%
Company Profile
- Volume Average 78.9K
- Market Capitalization 308.99M
- Employee 167
- CEO Mr. Sujal M. Patel
- Headquarters Seattle,WA,US
- IPO Date 2020-08-07
-
Website
https://www.nautilus.bio 
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
